Positron emission tomography (PET), immuno‐PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship
2006; Wiley; Volume: 97; Issue: 5 Linguagem: Inglês
10.1111/j.1464-410x.2006.06125.x
ISSN1464-410X
AutoresNathan Lawrentschuk, Ian D. Davis, Damien Bolton, Andrew M. Scott,
Tópico(s)Bladder and Urothelial Cancer Treatments
ResumoBJU InternationalVolume 97, Issue 5 p. 916-922 Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship NATHAN LAWRENTSCHUK, Corresponding Author NATHAN LAWRENTSCHUK Departments of Surgery, Urology and Medicine, University of Melbourne, Ludwig Institute for Cancer Research and Centre for PET, Austin Hospital, Heidelberg, Victoria, AustraliaNathan Lawrentschuk, Centre for PET, Level 1 HSB, Austin Hospital, Studley Road, Heidelberg, Victoria. 3084, Australia. e-mail: [email protected]Search for more papers by this authorIAN D. DAVIS, IAN D. DAVIS Departments of Surgery, Urology and Medicine, University of Melbourne, Ludwig Institute for Cancer Research andSearch for more papers by this authorDAMIEN M. BOLTON, DAMIEN M. BOLTON Departments of Surgery, Urology and Medicine, University of Melbourne,Search for more papers by this authorANDREW M. SCOTT, ANDREW M. SCOTT Departments of Surgery, Urology and Medicine, University of Melbourne, Ludwig Institute for Cancer Research and Centre for PET, Austin Hospital, Heidelberg, Victoria, AustraliaSearch for more papers by this author NATHAN LAWRENTSCHUK, Corresponding Author NATHAN LAWRENTSCHUK Departments of Surgery, Urology and Medicine, University of Melbourne, Ludwig Institute for Cancer Research and Centre for PET, Austin Hospital, Heidelberg, Victoria, AustraliaNathan Lawrentschuk, Centre for PET, Level 1 HSB, Austin Hospital, Studley Road, Heidelberg, Victoria. 3084, Australia. e-mail: [email protected]Search for more papers by this authorIAN D. DAVIS, IAN D. DAVIS Departments of Surgery, Urology and Medicine, University of Melbourne, Ludwig Institute for Cancer Research andSearch for more papers by this authorDAMIEN M. BOLTON, DAMIEN M. BOLTON Departments of Surgery, Urology and Medicine, University of Melbourne,Search for more papers by this authorANDREW M. SCOTT, ANDREW M. SCOTT Departments of Surgery, Urology and Medicine, University of Melbourne, Ludwig Institute for Cancer Research and Centre for PET, Austin Hospital, Heidelberg, Victoria, AustraliaSearch for more papers by this author First published: 06 April 2006 https://doi.org/10.1111/j.1464-410X.2006.06125.xCitations: 24Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Lindner V, Lang H, Jacqmin D. Pathology and genetics in renal cell cancer. In D Jacqmin ed, EAU Update Series: Renal Cell Cancer. Oxford, UK: Elsevier, 2003: 197–208 2 Novick AC. Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. Semin Oncol 1995; 22: 29–33 3 Brush JP. Positron emission tomography in urological malignancy. Curr Opin Urol 2001; 11: 175–9 4 Hara T. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001; 42: 1815–7 5 Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002; 75 (Spec no): S24–30 6 Ramdave S, Thomas GW, Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825–30 7 Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171: 1806–9 8 Majhail NS, Urbain JL, Albani JM et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995–4000 9 Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60: 395–400 10 Chang CH, Shiau YC, Shen YY, Kao A, Lin CC, Lee CC. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography – a preliminary report. Urol Int 2003; 71: 306–9 11 Miyakita H, Tokunaga M, Onda H et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9: 15–8 12 Brouwers AH, Dorr U, Lang O et al. 131I–cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG–PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 2002; 23: 229–36 13 Safaei A, Figlin R, Hoh CK et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57: 56–62 14 Montravers F, Grahek D, Kerrou K et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41: 78–84 15 Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 510–5 16 Hoh CK, Seltzer MA, Franklin J, DeKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol 1998; 159: 347–56 17 Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. [Positron emission tomography in diagnosis of renal cell carcinoma]. Urologe A 1996; 35: 146–50 18 Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results]. Urologe A 1995; 34: 138–42 19 Kocher F, Grimmel S, Hautmann R et al. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994; 35 (Suppl.): 223P–224P 20 Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F) -fluoro-d-glucose: pilot animal and human studies. J Urol 1991; 146: 1470–4 21 Lawrentschuk N, Gani J, Rowden R, Esler S, Bolton DM. Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review BJU Int 2005; 96: 291–5 22 Heidenreich A, Ravery V. Preoperative imaging in renal cell cancer. World J Urol 2004; 22: 307–15 23 Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Rel Res 2003; 415 (Suppl): S120–8 24 Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001; 31: 321–9 25 Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28 (Suppl. 2): 36–41 26 Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335–54 27 Koh WJ, Rasey JS, Evans ML et al. Imaging of hypoxia in human tumors with 18F-fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199–212 28 Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265–80 29 Lawrentschuk N, Poon AM, Foo SS et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 2005; 96: 540–6 30 Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36: 1595–601 31 De Certaines JD, Larsen VA, Podo F, Carpinelli G, Briot O, Henriksen O. In vivo 31P MRS of experimental tumours. NMR Biomed 1993; 6: 345–65 32 Mathews D, Oz OK. Positron emission tomography in prostate and renal cell carcinoma. Curr Opin Urol 2002; 12: 381–5 33 Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 2004; 18: 269–88 34 Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44: 2027–32 35 Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997; 27: 10–29 36 Brouwers A, Verel I, Van Eerd J et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 2004; 19: 155–63 37 Oosterwijk E, Brouwers A, Boerman OC et al. Monoclonal antibody therapy of kidney cancer. Cancer Treat Res 2003; 116: 199–212 38 Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7: 109–15 39 Steffens MG, Oosterwijk E, Kranenborg MH et al. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med 1999; 40: 829–36 40 Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390–8 41 Divgi CR, O'Donoghue JA, Welt S et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45: 1412–21 Citing Literature Volume97, Issue5May 2006Pages 916-922 ReferencesRelatedInformation
Referência(s)